Dr. Scott Liu, the co-founder and Head of Strategic Advisory Committee at Shanghai Henlius Biotech Inc., a global biopharmaceutical company focusing on the development, production and commercialization of high-quality and affordable biosimilar, biobetter and novel therapeutic monoclonal antibodies. Dr. Liu has more than 25 years of experience in biopharmaceutical R&D, manufacturing and quality management. Prior to setting up Henlius in 2010, he has previously had postdoctoral training in Biology at Stanford University and has served several executive positions at United Biomedical, the Founding Director of the Biologics QC Department at Bristol-Myers Squibb Technical Operations, and the Director of QAL (QC) at Amgen Inc. Fremont (now Boehringer Ingelheim Fremont Inc.). Dr. Liu was the recipient of the Bristol-Myers Squibb “Technical Operations Presidential Award” in 2004. Furthermore, Dr. Liu led the promotion of industry-wide adoption of single-use manufacturing technology to support the production of clinical and commercial monoclonal antibody therapeutics, and actively participated in the development of Technical Guidelines of Biosimilar Development and Evaluation to promote the innovation and globalization of the biopharmaceutical industry in China. He received his Ph.D. degree in Biology from the Purdue University.

Dr. Weidong Jiang, the co-founder and Chief Scientific Officer at Shanghai Henlius Biotech Inc., graduated from Hangzhou University with a bachelor degree of biology, and Chinese Academy of Sciences with a master degree of cell biology. He later continued his Ph.D. study in Microbiology and Molecular Biology in the University of Giessen in Germany. After that, he did his post-doctoral research at University of California. Following his academic career, he developed his expertise in biopharmaceutical R&D and production, including drug discovery, antibody/protein engineering, production cell line development, process optimization, and regulatory filing, by serving as a senior scientist and/or director for companies such as Applied Molecular Evolution Inc. and Vasgene Therapeutics Inc. 

Mr. Wenjie Zhang is Executive Director, Chief Executive Officer and President of Shanghai Henlius Biotech, Inc.

Mr. Zhang has 25 years of commercial experience in the pharmaceutical industry. Before joining Henlius in March 2019, he was the Executive Director, Marketing for Amgen Japan and Asia Pacific region at first and then being promoted as General Manager of Amgen China where he was leading company’s overall efforts in expanding business into Chinese market and help Chinese patients to access Amgen’s innovative medicines. During his tenure as General Manager, Amgen China has effectively built up its commercial infrastructure, organization, and competency. He successfully launched Repatha^® (evolocumab), Amgen’s first product in China. Prior to Amgen, Mr. Zhang worked as Vice President, Oncology for Roche in Shanghai, China, where he was managing a strong team of 850 sales and marketing staff in the oncology franchise marketing business unit. He significantly grew the Roche oncology portfolio including Avastin^® (bevacizumab), Tarceva ^®(erlotinib) and MABTHERA^® (rituximab) in the China market. He also led Roche China oncology franchise in pipeline planning, franchise strategy, and franchise marketing. Before then, Mr. Zhang served as the head of Business Development at Bayer Schering Pharma, Asia Pacific Headquarters, Product Manager of US Marketing, Business Development Manager and Deputy Director of Global Marketing at Bayer Pharmaceuticals USA. In this role, he led the fastest growing business unit within Bayer China. He also had dual responsibility as Head of the same business unit for Asia Pacific region. He succeeded in launching multiple products in China including Nexavar, Kogenate and Betaferon. Mr. Zhang obtained his MBA from the Yale University School of Management in 1998. He graduated with a B.S. in microbiology from Shandong University in Jinan, China in 1990.

Mr. James Guo, Senior Vice President and Secretary of the Board, graduated from Genetics and Genetic Engineering Department of Fudan University, and holds a MBA degree from Zhejiang University. He has previously served as research manager, vice president and chief engineer in Hangzhou Jiuyuan Gene Engineering Co., Ltd., Hangzhou Taishi Biotechnology Co., Ltd., Zhejiang Cifu Pharmaceutical Co. and Shanghai Chemo Wanbang Biopharma Co., Ltd. James is experienced in biopharmaceutical development and production, and familiar with all types of national laws and regulations. He has been involved in the development of a Category II new drug which is the first listed recombinant human granulocyte colony-stimulating factor (rhG-CSF) injection in China. He was awarded Outstanding Technology Development Talent of Hangzhou, Second Prize for Science and Technology Progress Award of Zhejiang Province and First Prize for Science and Technology Progress Award of Hangzhou. In addition, he is the vice-chairman of Shanghai Biopharmaceutics Industry Association Monoclonal Antibody Drug Professional Committee currently.

Ms. Cecie Jiang, Senior Vice President of Quality, received her Bachelor degree in Applied Chemistry from China Agricultural University and Master degree in Microbiology from the University of Wisconsin – Madison. She has previously served the Vice President of Global Quality and Compliance for TWi Pharmaceuticals, Director of Quality for several companies including Boehringer Ingelheim, Stryker, Aphena Pharma Solutions. She also worked at Novartis, Perrigo and Bristol-Myers Squibb as QO Project Manager and QC Sr. Supervisor. Cecie has over 20 years of leadership experience in the pharmaceutical, medical device, and biotech industries with strong knowledge in quality system management, manufacturing transfers, QC Laboratories, and validations. She has led multiple successful global regulatory inspections and ISO audits for different companies.

Mr. Xinlei Li, Vice President and Chief Financial Officer, is responsible for listing investment management, market value management and financial operation management. Previously, Mr. Li served as vice president and the general manager of investor relations and capital development department of Fosun Pharma. Mr. Li obtained a Bachelor of Science degree in Pharmacy from Sichuan University in 2004, a Master of Science degree from the University of Huddersfield in the U.K. in 2006, and a master’s degree from the IMBA Programme of Fudan University – Hong Kong University in 2016.

Ms. Ping Cao, Vice President of Business Development, graduated from Tianjin University with a BS in Material Science & Engineering and MS in Chemical Engineering and also obtained her MS in Organic Chemistry at Michigan State University. She previously worked at Tyger Scientific, Ferro,Bristol-Myer Squibb (BMS) and Abzena, and held positions of Director of Sales and Marketing, Sr. Manager of Business Development, Associate Director of Global Manufacturing and Supply Chain, and Sr. Director of Business Development. At Tyger Scientific, Ms. Cao increased the business revenue 600% in 4 years. At BMS, she was responsible for global business development at CMO (contract manufacture operation) and accomplished significant sales growth. Then Ms. Cao joined business development team focusing on technology transactions. She negotiated and executed 36 technology collaboration deals to expedite the company’s drug discovery and development process. As a reward for her accomplishment, Ms. Cao received the Distinguished Employee Award, Innovation Award etc. at BMS. At Abzena, she developed and executed the business strategy of offering integrated contract manufacture service of biologics and antibody drug conjugates based on company core technologies of antibody drug conjugation and humanization, which greatly enhanced the company’s business growth worldwide.